GeneXpert MTB/RIF Is Superior to BBD Max MDR-TB for Diagnosis of Tuberculosis (TB) in a Country with Low Incidence of Multidrug-Resistant TB (MDR-TB).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

1. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.The Cochrane database of systematic reviews · 2022
   Pooled it
2. Diagnostic accuracy of the BD MAX MDR-TB assay on sputum and tongue swabs forMicrobiology spectrum · 2026
   Article
3. Comparative Analysis of 2 Diagnostic Devices for Detection ofOpen forum infectious diseases · 2025
   Article
4. Accuracy of the InnowaveDX MTB/RIF test for detection ofEmerging microbes & infections · 2023
   Article
5. The Value of GeneXpert MTB/RIF for Detection in Tuberculosis: A Bibliometrics-Based Analysis and Review.Journal of analytical methods in chemistry · 2022
   Review
6. Performance Comparison of GeneXpert MTB/RIF and ProbeTec ET Tests for Rapid Molecular Diagnosis of Extrapulmonary Tuberculosis in a Low TB/MDR-TB Incidence Country.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021
   Article
7. Evaluation of the BD MAX™ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
   Article
8. The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.Translational research : the journal of laboratory and clinical medicine · 2020
   Review
9. A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB.PloS one · 2020
   Article
10. Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".Journal of clinical microbiology · 2019
    Article
11. Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays.Journal of clinical microbiology · 2019
    Article

Corrections and comments

• Commented on by
  Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays.2019
• Commented on by
  Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays".2019

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as